

Research Activities Newsletter

The latest news and announcements



In This Issue

In the News: Congratulations to the following awardees!!!.....	2
Grant Clinic	4
Notice of Changes to Funding Opportunities	5
Notice of Intent to Publish.....	5
Notice of Special Interest.....	6
Policy Notices	6
NIH Funding Opportunities: Request for Applications (RFA)	7
Addictions.....	7
Aging	8
HIV/AIDS	8
Miscellaneous	8
NIH Funding Opportunities (PAR)	9
Miscellaneous	9
NIH Funding Opportunities: Program Announcements (PA).....	10
Limited Submissions.....	11
Research Opportunities from Past Newsletters	11
Words to Live By.....	11

In the News: Congratulations to the following awardees!!!



Katherine Balantekin, Assistant Professor of Exercise and Nutrition Sciences received a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the project entitled, *The Intersection between Loss of Control Eating and Obesity: The Role of Restriction and Food Reinforcement*. The project continues to explore the relationships among LOC eating, parental restriction, and the reinforcing value of food in a sample of 7-10 year-old children at risk for obesity.



Gregory Homish, Professor and Chair of the Department of Community Health and Health Behavior is Co-PI (with Co-PI: Ken Leonard, Psychiatry) on a continuation award from the National Institute on Alcohol Abuse and Alcoholism/NIH, for the T32-training grant entitled, *Research Training on Alcohol Etiology and Treatment*. **Heather Orom**, Associate Professor in CHHB and SPHHP Associate Dean for Equity, Diversity and Inclusion, is a member of the training committee.



Established in 2000, the interdisciplinary training program provides postdoctoral and predoctoral trainees with research training related to alcohol problems.



David Hostler, Professor and Chair of Exercise and Nutrition Sciences is PI on a new award from Ohio State University/US Office of Naval Research for the project entitled, *Identifying Adverse Modes via Human-machine Cybernetic Modeling*. The primary objectives of this study are to: 1) examine the effects of hypoxia on vestibular function, specifically vestibular ocular reflex elicited by a roll-tilt, and 2) examine the effects of hypoxia on the CBF-Vestibular connection in males and females. Cerebral blood flow will be measured with transcranial doppler and internal carotid artery and vertebral artery flow in normoxia and while breathing a hypoxic gas mixture that simulates 4572 m (15,000 ft). During all testing, non-invasive measures of heart rate, blood pressure, and end tidal CO₂ will be taken.

Dr. Hostler also is PI on a new contract from CREARE, LLC/Office of Navel Research for Phase II of the research project entitled, *Physiological Monitoring to Accelerate Safe Decompression*. Decompression sickness is a leading risk and time-limiting factor for diving operations. At the present time, there is no technology to tailor decompression schedules to the physiological state of individual divers. Dr. Hostler's involvement in Phase II will include developing, demonstrating and validating the underwater ultrasound sensor prototype. Dr. Hostler will prepare and conduct hyperbaric studies, evaluate prototype(s) for form and fit, provide recommendations for things to change in Phase II, and design the framework of the Phase II human study.




Douglas Landsittel, Chair of Biostatistics is PI on an award transferred from the University of Pittsburgh for the project entitled, *TCH Analysis*. Dr. Landsittel will provide statistical consultation for grant submissions and assist with manuscripts on biomarker imaging studies and other work coming from the laboratory of Dr. Panigraphy. He will attend investigator meetings, contribute to discussions of statistical modeling approaches and study designs, and assist in writing statistical methods sections and interpreting results.



Lucia Leone, Associate Professor of Community Health and Health Behavior is PI on a new award from the National Institute on Minority Health and Health Disparities/NIH for the project entitled, *Adapting the Veggie Van Mobile Market Intervention to Address Disparities in Nutrition Security Among College Students*. This research proposes an innovative shift from merely providing emergency food assistance to promoting nutrition security. It plans to adapt the Veggie Van—an evidence-based approach to increasing access to healthy food in underserved communities—to a college context. The adapted intervention will be tested at the University at Buffalo, the largest university in the State University of New York (SUNY) system, known for its diverse student population. The study will utilize implementation science adaptation frameworks to assess needs, engage stakeholders, monitor and document adaptations, and evaluate the effects of adaptations. Findings from this study will be used to develop an adaptable model that targets the needs of students facing nutrition insecurity and provide consistent access to fresh fruits and vegetables and support for healthy eating. Ultimately, aligning



with the National Strategy on Hunger and Nutrition, and focusing on student dignity and participation, this model can be used to enhance campus nutrition security nationwide. **Anne Mathiebe**, Research Assistant Professor in Community Health and Health Behavior is Co-I on the project.



Chang-Xing Ma, Associate Professor of Biostatistics is Co-I on a new award from the National Institute of Neurological Disorders and Stroke/NIH, (PI: Junghun Cho, Biomedical Engineering), for the research project entitled, *MRI-Based Quantitative Mapping of Oxygen Extraction Fraction in MS*. This project will establish a clinically readily applicable MRI toolset for qmOEF, which is validated and available to every MRI scanner.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health and SPHHP Associate Dean for Translational and Team Science is Co-I on a continuation award from the Agency for Healthcare Research and Quality, (PI: Sharon Hewner, Nursing), for the project entitled, *Implementing Personalized Cross-sector Transitional Care Management to Promote Care Continuity, Reduce Low Value Utilization, and Reduce the Burden of Treatment for High-need, High-cost Patients*. The project continues to study whether identifying HNHC patients at the point of transition between care settings, coupled with enhanced communication through an interoperable shared care plan, will facilitate referrals to care management, improve continuity, and reduce reliance on low-value care.



Jeffrey Miecznikowski, Professor and former Interim Chair of Biostatistics is Co-I on a new award (PI: Remi Adelaiye-Ogala, Medicine), from the National Cancer Institute/NIH for the project entitled, *Posttranslational Modifications of Glucocorticoid Receptor Associated with Drug-resistance in Prostate Cancer*. The central hypothesis is that induction of oncogenic GR in enzalutamide-resistant CRPC is modulated by PTM on GR, and inhibition of pGR, would re-sensitize treatment-resistant CRPC to enzalutamide. The following aims will be pursued to test the hypothesis: (i) Characterize ligand-dependent driven GR vs. PTM-driven GR expression and activity in patient-derived xenograft models using multi-omic assays, (ii) Perform functional studies to determine the mechanism of PTM driven GR vs. ligand-dependent GR activity in lethal PCa (iii) Determine the therapeutic efficacy and benefit of targeting AKT-GR-AR as a novel therapeutic approach for lethal prostate cancers. Impact: The results from this study will significantly expand our knowledge of the mechanism of PTMs in advanced PCa and the role their unique signatures play in disease progression and resistance to AR-targeted therapy.

Dr. Miecznikowski is also Co-I on a continuation award from the National Institute of Dental & Craniofacial Research/NIH, (PI: Jill Kramer, Oral Biology), for the research project entitled, *Analysis of MyD88-mediated Immune Activation in Sjogrens Syndrome Pathogenesis*. This project continues to discover novel pathways that can target to treat pSS and other autoimmune diseases.



James Olson, Research Professor of Epidemiology and Environmental Health is PI on a new award from American University of Beirut to continue working on the project entitled, *½ The Global Environmental and Occupational Health Research and Training Hub for the Middle East and North African Region (GEOHealth-MENA) – Lebanon*. The U01 proposed research will evaluate the pathways of pesticide exposure among agricultural workers, investigate the effect of such exposure on neurobehavioral performance, and examine the role of social factors in modifying exposure and outcome within the context of this at-risk vulnerable population.




Kirk Personius, Clinical Associate Professor of Rehabilitation Science is Co-I on an award from the National Institute of Allergy and Infectious Diseases/NIH (PI: Elizabeth Wohlfert, Microbiology & Immunology) for the project entitled, *T Regulatory Cell Responses in Toxoplasma-infected Muscle*. The study continues research to understand how regulatory T cells can be manipulated in the context of chronic infection.





Jean Wactawski-Wende, Dean of the SPHHP and SUNY Distinguished Professor of Epidemiology and Environmental Health and **Hailey Banack**, Research Assistant Professor of Epidemiology and Environmental Health are MPIs on the continuation of their award from the National Institute on Aging/NIH for the research project entitled, *MASS: Muscle and Disease in Postmenopausal Women*. This study continues addressing a key knowledge gap in the extent to which insulin-glucose homeostasis is associated with loss of muscle mass over time in aging women and whether this varies by race/ethnicity. The feedback loop between impaired insulin-glucose homeostasis and loss of skeletal muscle mass will also be examined.



Meng Wang, Associate Professor of Epidemiology and Environmental Health, is Co-I on a new award (PI: Eun-Hye Enki Yoo, Geography) from the U.S. Environmental Protection Agency for the project entitled, *Improving Air Quality Monitoring for Buffalo's African American Community*. To address the chronic and significant health problem of air quality, the proposed study aims to: 1) collect ambient air pollution data of the marginalized communities to assess air pollution exposures at fine spatial and temporal scale; 2) identify primary sources of air pollutants by mapping the spatial and temporal variations in air pollutants; 3) assess the associations between spatially and temporally resolved air pollution exposure and health outcomes obtained from both retrospective and prospective studies; and 4) distribute and share community-specific air quality data to develop just-in-time interventions (short-term outcome) and to develop policies to mitigate harms and reduce air pollution emissions (mid- and long-term outcomes).

Dr. Wang is PI on a continuation award from the National Institute of Environmental Health Sciences/NIH for the research project entitled, *Air Pollution, Coronary Events, Atherosclerotic Progression in a Susceptible Population*. The study continues to examine whether exposure to air pollutants alters coronary biological process, accelerates disease progression, and contributes to coronary heart disease in 3500 patients in Beijing. **Jeffrey Miecznikowski**, Professor and former Interim Chair of Biostatistics and **Lina Mu**, Associate Professor of Epidemiology and Environmental Health are Co-Investigators.



Gregory Wilding, Professor of Biostatistics is Co-I on the continuation award from the National Institute of Allergy and Infectious Diseases/NIH, (PI: Jonathan Lovell, Biomedical Engineering), for the research project entitled, *Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria Vaccine*. The project continues work to on develop a vaccine that will block the transmission of malaria by focusing the immune response towards the same target epitope of a potent monoclonal.

Grant Clinic

[NOT-OD-24-123](#) - Report Data Management and Sharing (DMS) Plan Activities in the Research Performance Progress Report (RPPR)

This Notice informs the extramural research community of planned changes to the Research Performance Progress Report (RPPR) instructions to address the NIH Data Management and Sharing Policy. Upon receiving approval from the Office of Management and Budget (OMB) Office of Information and Regulatory Affairs (OIRA), NIH will issue new DMS RPPR questions that align with the [NIH Final Policy on Data Management and Sharing](#), to include updates on the status of data sharing, repositories and unique identifiers for data that have been shared. The updated NIH RPPR Instruction Guide will be posted to the [Research Performance Progress Report \(RPPR\)](#) page upon approval from OIRA. NIH plans to implement the new questions for RPPRs submitted on or after October 1, 2024.

[NOT-DA-24-017](#) – NIDA MERIT Awards for Early Stage Investigators (ESI)

Through this Notice, the National Institute on Drug Abuse (NIDA) announces its use of the Method to Extend Research in Time (MERIT) (R37) Award to provide longer term grant support to Early Stage Investigators (ESIs) to give them flexibility and opportunity for creativity and innovation, and additional time to successfully launch their careers before having to submit renewal applications.



Notice of Changes to Funding Opportunities

[NOT-OD-24-117](#)

Notice of NCCIH Participation in “Notice of Special Interest (NOSI): Climate Change and Health”

This Notice informs potential applicants that the National Center of Complementary and Integrative Health (NCCIH) is participating in [NOT-ES-22-006: Notice of Special Interest \(NOSI\): Climate Change and Health.](#)

Notice of Intent to Publish

[NOT-HS-24-014](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Examining the Impact of Artificial Intelligence (AI) on Healthcare Safety (R18)

AHRQ intends to publish a NOFO to invite grant applications that support healthcare safety by determining (1) whether and how certain breakthrough uses of Artificial Intelligence (AI) systems can affect patient safety; and (2) how AI systems can be safely implemented and used. AI has the potential to improve the safety, effectiveness, efficiency, accessibility, and affordability of healthcare. However, as with most technologies, this potential must be balanced by identifying and mitigating possible risks for patient harm and user burden. The NOFO will focus on assessing the impact, both positive and negative, of actual AI deployments in healthcare delivery systems and how that impact can be affected by implementation and use strategies. AHRQ intends to publish the NOFO in Spring 2024.

[NOT-MD-24-015](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U01 – Clinical Trial Optional)

The National Institute on Minority Health and Health Disparities (NIMHD), with other NIH Institutes and Centers (ICs) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications from National Cancer Institute (NCI)-designated Cancer Centers with existing community outreach and collaborations with American Indian and Alaska Native populations for research on improving cancer outcomes. [Notice of Correction to Key Dates for NOT-MD-24-015](#), [NOT-MD-24-019](#)

[NOT-CA-24-048](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)

The National Cancer Institute (NCI) intends to publish a NOFO as a request for applications to solicit applications supporting multi-level intervention studies that address individual and system level barriers to transitions from pediatric to adult care for survivors of childhood and adolescent cancers. The goal of this opportunity is to support the development and testing of interventions and strategies that promote high-quality transitional care and continued engagement of survivors of childhood and adolescent cancers to ensure these survivors receive appropriate surveillance and care into adulthood. The NOFO is expected to be published in June 2024 with an expected application due date in October 2024.

[NOT-MD-24-018](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Environmental Health Disparities Centers (P50)

The National Institute on Minority Health and Health Disparities in partnership with the National Institute on Environmental Health Sciences and the National Cancer Institute intends to promote the continuation of The Environmental Health Disparities Centers program (referred to as the EHD Centers) by publishing a NOFO to solicit applications. The EHD Centers will conduct environmental health disparities and environmental justice research, engage in research capacity building, and provide training across diverse disciplines and backgrounds with a disease agnostic focus. The program will focus on the prevention and mitigation of adverse environmental exposures that disproportionately impact racial, ethnic, under resourced and underserved populations. The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024.



Notice of Special Interest

[NOT-OD-24-119](#)

Research Opportunities Centering the Health of Women Across the HIV Research Continuum

The NIH Office of Research on Women's Health and Office of AIDS Research, in partnership with our Institute, Center, and Office partners are issuing this Notice to highlight interest in receiving HIV research and training grant applications that explicitly and intersectionally center the health needs of cisgender women and girls, and gender-diverse people. Despite tremendous scientific advances that have translated to substantial progress in confronting the HIV epidemic, women – and particularly women of color, young women and girls, and transgender women – and gender-diverse individuals remain disproportionately affected by HIV. An intersectional, equity-informed, data-driven approach is essential to advance HIV research and clinical care for all women with or impacted by HIV across their lifespan and to end the HIV pandemic ([Barr et al, 2024](#)).

[NOT-DA-25-030](#)

Exploring the Effects of Endocannabinoids and Exogenous Cannabinoids on Brain Development

The purpose of this NOSI is to encourage investigators to submit grant applications to the NIDA to investigate the roles of endocannabinoids and the effects of cannabinoid exposure in the developing brain, from fetal development through young adulthood in humans and animal models. Funding mechanisms: R01, R21, R03, K01, K08, K25, K99, F32. This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through May 8, 2028.

[NOT-CA-24-056](#)

Mechanisms Driving Obesity and Prostate Cancer Risk

The purpose of this NOSI is to promote studies examining the mechanisms by which obesity drives aggressive prostate cancer (PCa) risk. Mechanisms Driving Obesity and Prostate Cancer Risk. This NOSI applies to Application Due Dates on or after October 5, 2024, and subsequent receipt dates. **Expiration Date:** September 8, 2025.

[NOT-DA-24-029](#)

High-Priority Interest in Enhance Data Science Research Training in Addiction Research

The purpose of this Notice is to highlight NIDA's high-priority interest in receiving applications that will support training and career development in Data Science within the overall field of drug addiction research. Grants supported under this Notice can be from individuals at formative career stages or from established investigators proposing training programs that will support early career scientists. This notice applies to due dates on or after October 12, 2024 and subsequent receipt dates through May 8, 2027.

[NOT-OD-24-096](#)

Promoting Data Reuse for Health Research

This Notice solicits *competitive revision applications* that focus on data reuse and secondary data analysis in NIH-funded data repositories and knowledgebases to advance scientific inquiry and address health research questions. **Eligibility:** The application's project and budget periods must be within the currently approved project period for the existing parent award. At the time of application submission, the parent award must have a minimum of two years remaining. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 4, 2026.

Policy Notices

[NOT-OD-24-084](#) – **Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025**

This notice provides the research and research training community an overview of application and peer review changes impacting grant applications submitted for due dates on or after January 25, 2025, including:

- Simplified Review Framework for Most Research Project Grant Applications
- Revisions to the NIH Fellowship Application and Review Process
- Updates to Reference Letter Guidance
- Updates to NRSA Training Grant Applications
- Updated Application Forms (FORMS-I)
- Common Forms for Biographical Sketch and Current and Pending (Other) Support



Although each of these initiatives has specific goals, they are all meant to simplify, clarify, and/or promote greater fairness towards a level playing field for applicants throughout the application and review processes. NIH will release additional details and guidance on these initiatives throughout 2024 which will be cross-referenced in this notice as well.

[NOT-OD-24-085](#) – **Simplified Review Framework for NIH Research Project Grant Applications**

This notice provides an update and implementation plans for the simplified framework for peer review for the majority of research project grant applications announced in October ([NOT-OD-24-010](#)). It updates and clarifies impacted activity codes, plans for updating funding opportunities, and timing for application forms availability. NIH remains on schedule to implement the simplified review framework for application due dates on or after January 25, 2025.

[NOT-OD-24-086](#) – **New NIH “FORMS-I” Grant Application Forms and Instructions coming for Due Dates on or after January 25, 2025**

This notice informs the applicant and recipient communities of changes to grant application forms and application guide instructions for due dates on or after January 25, 2025. The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- PHS 398 Research Training Program Plan
- PHS Fellowship Supplemental Form
- PHS Assignment Request Form
- PHS 398 Cover Page Supplement Form

[NOT-OD-24-107](#) – **Implementation of Revisions to the NIH and AHRQ Fellowship Application and Review Process**

This notice announces changes to the application and peer review process for NIH and AHRQ fellowship applications, starting with submissions with due dates after January 25, 2025. The overall goal of the changes is to facilitate the mission of fellowship peer review – to identify the most promising candidates and the individualized training opportunities that will assist them along their paths to support the advancement of the biomedical research enterprise. The revised fellowship application and review process will be effective for application due dates on or after January 25, 2025, for the programs using the following activity codes: F30, F31, F32, F33, and F99/K00.

[NOT-OD-24-115](#) – **Publication of the Revised NIH Grants Policy Statement (Rev. April 2024) for Fiscal Year 2024**

The NIH announces publication of the updated NIH Grants Policy Statement (NIHGPs, rev. April 2024). The NIHGPs provides both up-to-date policy guidance that serves as NIH standard terms and conditions of award for all NIH grants and cooperative agreements, and extensive guidance to those who are interested in pursuing NIH grants. This update is applicable to all NIH grants and cooperative agreements with budget periods beginning on or after October 1, 2023.

[NOT-OD-24-104](#) – **Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2024**

This Notice supersedes [NOT-OD-23-076](#) and establishes stipend levels for fiscal year (FY) 2024 Kirschstein-NRSA awards for undergraduate, predoctoral, and postdoctoral trainees and fellows, as shown in the tables below which reflects the Further Consolidated Appropriations Act, 2024 ([Public Law 118-047](#)), signed into law on March 23, 2024.

NIH Funding Opportunities: Request for Applications (RFA)

Addictions

[RFA-AA-24-007](#) – (P50 Clinical Trial Optional)

Specialized Alcohol Research Centers

[RFA-AA-24-008](#) – (P60 Clinical Trial Optional)

Comprehensive Alcohol Research Centers

The NIAAA supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol-related problems, and other health-related consequences across the lifespan. The NIAAA Centers Program provides leadership in research, and research methodology development on a wide variety of topics relevant to the Institute’s mission. Topics include but are not limited to, the nature, etiology, genetics, diagnosis, treatment, and prevention of AUD, alcohol-related end-organ diseases, and



their biomedical, psychosocial, and economic consequences across the lifespan and minority health and other NIH-designated populations that experience health disparities. [RFA-AA-24-008](#) – This Notice of Funding Opportunity (NOFO) invites applications for Comprehensive Alcohol Research Centers using the P60 mechanism which requires a dissemination core to initiate and expand community education related to the activities of the center. **Application Due Date:** November 15, 2024. **Expiration Date:** November 16, 2024.

Aging

[RFA-AG-25-004](#) – (UG3/UH3 Clinical Trial Required)

Safety and Early Efficacy Studies in Psychedelic-Assisted Therapy for Chronic Pain in Older Adults

This NOFO will support a clinical trials network involving multiple institutions to collect safety and early efficacy data in defined groups of older adults living with specific chronic pain conditions through a biphasic mechanism. The first phase will involve safety and efficacy studies in healthy older adults, and the second phase will involve expanded safety and efficacy studies in older adults with chronic pain conditions. **Application Due Date:** October 10, 2024. **Expiration Date:** October 11, 2024.

HIV/AIDS

[RFA-MH-25-185](#) – (R01 Clinical Trial Optional)

[RFA-MH-25-186](#) – (R21 Clinical Trial Optional)

Advancing HIV Service Delivery through Pharmacies and Pharmacists

The NOFO is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes the advancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. [RFA-MH-25-186](#) uses the R21 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism. **Application Due Date:** August 13, 2024. **Expiration Date:** August 14, 2024.

Miscellaneous

[RFA-NR-24-006](#) – (R01 Clinical Trial Optional)

Understanding the Intersection of Social Inequities to Optimize Health and Reduce Health Disparities: The Axes Initiative

This funding opportunity solicits research to examine the pathways through which social determinants of health (SDOH), and related biological, psychological, and behavioral factors impact health and health disparities at intersections of privileged and/or oppressed social statuses such as race, ethnicity, socioeconomic status, sexual orientation, and ability. SDOH is a key pathway of interest, therefore examination of federal, state, local, or organizational level policies, programs, or practices, and/or conditions of daily life (e.g., concentrated disadvantage, quality employment and education, housing, and food) on health outcomes at intersections of social statuses is required. **Application Due Dates:** July 5, 2024 and February 14, 2025. **Expiration Date:** March 11, 2025.

[RFA-ES-24-001](#) – (U45 Clinical Trials Not Allowed)

Hazardous Materials Worker Health and Safety Training

NIEHS invites applications for cooperative agreements to support the development and delivery of model programs for the training and education of workers engaged in activities related to hazardous materials and waste generation, removal, containment, transportation, and emergency response. This funding opportunity announcement aims to use safety and health training to prevent and reduce work-related harm. *Only one application per institution is allowed.* **Application Due Date:** July 8, 2024. **Expiration Date:** July 9, 2024.

[RFA-DK-25-007](#) – (P30 Clinical Trial Optional)

Nutrition Obesity Research Centers

This Notice invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. *For companion NOFO*



[Nutrition Obesity Research Centers Research Resource Center \(RRC\) \(P2C-Clinical Trial Optional\)](#), please click the following link: [RFA-DK-25-011](#). **Application Due Dates:** October 9, 2024 and June 10, 2025. **Expiration Date:** June 11, 2025.

[RFA-OH-25-001](#) – (R21)

Exploratory/Developmental Research for World Trade Center Health Program Evidence-based Strategies to Improve Treatment Effectiveness, Diagnostic Practices, and Program Evaluation

NIOSH supports exploratory and developmental research which addresses diagnostic or treatment uncertainty with respect to individuals receiving monitoring and/or treatment under subtitle C of the James Zadroga 9/11 Health and Compensation Act of 2010 as amended. The Zadroga Act lists three broad research areas: 1) Physical and mental health conditions that may be related to the September 11, 2001, terrorist attacks; 2) Diagnosing WTC-related health conditions for which there has been diagnostic uncertainty; and 3) Treating WTC-related health conditions for which there has been treatment uncertainty. Research areas of interest include clinical, screening, diagnostic, epidemiological, treatment, prevention, translation, and program evaluation. The research should consider health equity initiatives in design, where possible.

Application Due Date: October 29, 2024. **Expiration Date:** November 28, 2024.

[RFA-NS-24-041](#) – (UG3/UH3 Clinical Trial Optional)

NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems

This Notice solicits research applications that propose implementation science methodology to embed existing evidence-based coordinated pain care models into a variety of public and private health care systems (HCS) where this type of care does not exist. This NOFO is intended to embed the coordinated care model under study into the health care delivery system of applicant institutions. **Application Due Date:** November 7, 2024. **Expiration Date:** November 8, 2024.

[RFA-MH-25-130](#) – (R34 Clinical Trial Required)

Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults

This NOFO seeks applications for pilot research to adapt, optimize and test empirically supported behavioral interventions that address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. In this pilot phase of effectiveness research, trials should be designed to evaluate the feasibility, acceptability, and potential effectiveness of the approach in real world settings, to conduct a preliminary test of the intervention's impact on target mechanisms and sleep and mental health outcomes, and to obtain preliminary data needed as a prerequisite a larger-scale effectiveness trial. **Application Due Date:** June 13, 2025. **Expiration Date:** June 14, 2025.

NIH Funding Opportunities (PAR)

Miscellaneous

[PAR-24-110](#) – (R01 Clinical Trials Optional)

Interventions to Reduce Sleep Health Disparities

The purpose of this initiative is to support non-pharmacological interventions to promote sleep health, reduce sleep health disparities, and examine sleep as a modifiable factor to reduce disparities for other health outcomes among populations that experience health disparities. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** September 8, 2027.

[PAR-24-202](#) – (Si2/R00 Clinical Trial Optional)

Lasker Clinical Research Scholars Program

This is a career development program to foster the development of early stage, independent clinical investigators. The NIH funds research and research training at extramural institutions, as well as within the NIH Intramural Research Program (IRP) to support the development of clinical treatments for disease and to improve human health. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or the Scholar can be considered to remain as an investigator within the intramural program. **Application Due Date:** August 30, 2024. **Expiration Date:** August 31, 2024.



NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-24-175](#) – Reissue of [PA-20-176](#)

Mentored Research Scientist Development Award (Parent K01 Independent Clinical Trial Required)

[PA-24-176](#) – Reissue of [PA-20-190](#)

Mentored Research Scientist Award (Parent K01 Independent Clinical Trial Not Allowed)

[PA-24-177](#) – Reissue of [PA-20-191](#)

Mentored Research Scientist Development Award (Parent K01 Independent basis Experimental Studies with Humans Required)

The purpose of the NIH Mentored Research Scientist Development Awards is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. **Expiration Date:** May 8, 2027.

[PA-24-178](#) – Reissue of [PA-20-171](#)

Independent Scientist Award (Parent K02 – Independent Clinical Trial Required)

[PA-24-179](#) – Reissue of [PA-20-174](#)

Independent Scientist Award (Parent K02 Independent Clinical Trial Not Allowed)

[PA-24-180](#) – Reissue of [PA-20-173](#)

Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Human Required)

The purpose of the NIH Independent Scientist Awards is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and “protected time” for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. **Expiration Date:** May 8, 2027.

[PA-24-181](#) – Reissue of [PA-20-202](#)

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)

[PA-24-182](#) – Reissue of [PA-20-203](#)

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)

[PA-24-183](#) – Reissue of [PA-20-201](#)

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Award programs is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and “protected time” to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. **Expiration Date:** May 8, 2027.

[PA-24-187](#) – Reissue of [PA-20-193](#)

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)

[PA-24-188](#) – Reissue of [PA-20-186](#)

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)

[PA-24-189](#) – Reissue of [PA-20-192](#)

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Basic Experimental Studies with Humans Required)

The purpose of the NIH Midcareer Investigator Awards in Patient-Oriented Research is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research



mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. **Expiration Date:** May 8, 2027.

[PA-24-190](#) – Reissue of [PA-20-197](#)

Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)

[PA-24-191](#) – Reissue of [PA-20-199](#)

Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

[PA-24-192](#) – Reissue of [PA-20-198](#)

Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Human Required)

The purpose of the Mentored Quantitative Research Career Development Award is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

Expiration Date: May 8, 2027.

[PA-24-193](#) – Reissue of [PA-20-187](#)

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)

[PA-24-194](#) – Reissue of [PA-20-188](#)

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)

[PA-24-195](#) – Reissue of [PA-20-189](#)

NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)

The purpose of the NIH Pathway to Independence Awards is to help postdoctoral researchers complete needed, mentored training and transition in a timely manner to independent, tenure-track or equivalent faculty positions. The K99/R00 award is intended to foster the development of an independent research program that will be competitive for subsequent independent funding and that will help advance the mission of the NIH. **Expiration Date:** May 8, 2027.

Limited Submissions

Only one application per institution is allowed for the following FOAs and prior approval from the OVPR is required to be the sole applicant. If interested in applying, please provide the OVPRED with notification 60 days prior to the deadline to ovpr.limitedsubmission@research.buffalo.edu before proceeding with the application.

[Limited Submission Funding Opportunities](#)

Prior Research Opportunities can be found on the SPHHP RAS website and by clicking the link below:

[Research Opportunities from Past Newsletters](#)

Words to Live By

“Every adversity, every failure, every heartache carries with it the seed of an equal or greater benefit.”

– Napoleon Hill

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras

